Financial Research and Analysis

Abstract

The industry is predicted to succeed in $65 bn by 2024 and to $120 bn by 2030 The pharmaceutical industry is currently valued at $41.7 bn. Generic drugs, with 71% market share, form the most important segment of the pharmaceutical industry in India. this is often set to grow as exports of generics to the US rise, as branded drugs worth $55 bn will become off-patent during 2017-2019. within the domestic market by revenue, Anti-Infectives (13.6%), Cardiac (12.4%) and Gastrointestinal (11.5%) had the most important market share. Under the assembly Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs), 47 applications with committed investments of INR 5366.35 crore are approved. The sector is supported by the subsequent Production Linked Incentive Schemes to spice up domestic manufacturing capacity, including of high value products across the worldwide supply chain. 1. PLI Scheme for Key Starting Materials (KSMs)/Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) (PLI 1.0) 2. Production-Linked Incentive (PLI) Scheme for Pharmaceuticals d (PLI 2.0)